Ikarian Capital, LLC Intra Cellular Therapies, Inc. Call Options Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	BUY	$43.8 - $56.99 $16.6 Million - $21.7 Million	380,000 New	380,000 $20.6 Million
Q1 2021 May 17, 2021	BUY	$30.8 - $39.51 $4.68 Million - $6.01 Million	152,000 Added 262.07%	210,000 $7.13 Million
Q4 2020 Feb 12, 2021	SELL	$23.34 - $32.22 $4.48 Million - $6.19 Million	-192,000 Reduced 76.8%	58,000 $1.85 Million
Q3 2020 Nov 16, 2020	SELL	$17.61 - $31.86 $3.69 Million - $6.67 Million	-209,300 Reduced 45.57%	250,000 $6.42 Million
Q2 2020 Aug 14, 2020	BUY	$14.35 - $26.64 $2.76 Million - $5.12 Million	192,200 Added 71.96%	459,300 $11.8 Million
Q4 2019 Jan 31, 2020	BUY	$7.26 - $38.49 $1.94 Million - $10.3 Million	267,100 New	267,100 $9.16 Million

418

88.6M

284K

105K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12.4B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.